Please check your internet connection and try again.
# Ecospirin (Aspirin Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antiplatelet properties. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, reducing gastric irritation.
## Primary Indications
* **Cardiovascular Risk Reduction:** Prevention of myocardial infarction and stroke in patients with established cardiovascular disease or at high risk.
* **Analgesic/Anti-inflammatory:** Management of mild to moderate pain and inflammation (though lower doses are typically used for antiplatelet effects).
## Adult Dosing
* **Cardiovascular Prevention:**
* 81 mg to 325 mg once daily.
* Dose selection depends on individual risk factors and clinician judgment. Higher doses are generally reserved for acute indications.
* **Pain/Inflammation:**
* Typically 325 mg to 650 mg every 4 to 6 hours as needed.
* Maximum daily dose is generally 4000 mg, but lower doses are preferred for chronic use due to safety concerns.
## Pediatric Dosing
Aspirin is generally **not recommended** in children and adolescents with viral illnesses (e.g., influenza, varicella) due to the risk of Reye's syndrome. Specific dosing for other indications in pediatrics is not established for this formulation and requires careful consideration and specialist consultation.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment based solely on the enteric-coated formulation, but caution is advised, especially in severe impairment, due to aspirin's potential for organ toxicity.
## Contraindications
* Known hypersensitivity to aspirin, salicylates, or NSAIDs.
* History of bronchospasm, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* Use in children and adolescents with viral infections (risk of Reye's syndrome).
* Severe hepatic impairment.
* Severe renal impairment.
* Late third trimester of pregnancy.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, gastritis, peptic ulceration, GI bleeding.
* **Hematologic:** Increased bleeding time, bruising, epistaxis, petechiae.
* **Hypersensitivity:** Bronchospasm, rash, urticaria, angioedema.
* **Other:** Tinnitus (especially at higher doses), dizziness, headache.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and Salicylates:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Selective Serotonin Reuptake Inhibitors (SSRIs):** Increased risk of bleeding, particularly in the GI tract.
* **Methotrexate:** Aspirin may increase methotrexate toxicity.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, beta-blockers):** NSAIDs can reduce their antihypertensive effect.
* **Uricosuric agents (e.g., probenecid):** Aspirin can interfere with their uricosuric effect.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding (e.g., bruising, melena, hematemesis).
* **GI Symptoms:** Assess for dyspepsia, abdominal pain, or other GI discomfort.
* **Renal Function:** Periodically assess in patients with risk factors for renal impairment.
* **Tinnitus:** Can be an early sign of salicylate toxicity.
## Clinical Pearls
* The enteric coating helps reduce but does not eliminate the risk of GI side effects. Advise patients to take with food if stomach upset occurs, though absorption may be slightly delayed.
* For acute antiplatelet effects, a non-enteric coated aspirin formulation may be preferred initially if available, followed by enteric-coated aspirin for maintenance.
* Discontinue aspirin at least 5-7 days before elective surgery or procedures where bleeding is a concern.
* Ensure patients understand the risks associated with aspirin use, especially concerning bleeding and Reye's syndrome in pediatric populations.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for definitive guidance.
